How to buy Anika Therapeutics stock

Anika Therapeutics, Inc is a biotechnology business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 154 staff and has a trailing 12-month revenue of around USD$125.5 million.

How to buy shares in Anika Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Anika Therapeutics. Find the stock by name or ticker symbol: ANIK. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Anika Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Anika Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Anika Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Anika Therapeutics share price

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-20.

52-week range	USD$22.01 - USD$75.715
50-day moving average	USD$36.5197
200-day moving average	USD$34.9119
Wall St. target price	USD$51
PE ratio	49.1795
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.793

Buy Anika Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Anika Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Anika Therapeutics under- or over-valued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's P/E ratio

Anika Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Anika Therapeutics shares trade at around 49x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1868. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$32.4 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM	USD$125.5 million
Operating margin TTM	18.26%
Gross profit TTM	USD$85.9 million
Return on assets TTM	3.94%
Return on equity TTM	4.2%
Profit margin	9.03%
Book value	$20.307
Market capitalisation	USD$537.3 million

TTM: trailing 12 months

Shorting Anika Therapeutics shares

There are currently 1.8 million Anika Therapeutics shares held short by investors – that's known as Anika Therapeutics's "short interest". This figure is 11.8% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting Anika Therapeutics shares can be evaluated.

Anika Therapeutics's "short interest ratio" (SIR)

Anika Therapeutics's "short interest ratio" (SIR) is the quantity of Anika Therapeutics shares currently shorted divided by the average quantity of Anika Therapeutics shares traded daily (recently around 136994.46550417). Anika Therapeutics's SIR currently stands at 13.19. In other words for every 100,000 Anika Therapeutics shares traded daily on the market, roughly 13190 shares are currently held short.

However Anika Therapeutics's short interest can also be evaluated against the total number of Anika Therapeutics shares, or, against the total number of tradable Anika Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anika Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Anika Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.151% of the tradable shares (for every 100,000 tradable Anika Therapeutics shares, roughly 151 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Anika Therapeutics.

Find out more about how you can short Anika Therapeutics stock.

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $22.01 up to $75.715. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.1048. This would suggest that Anika Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Anika Therapeutics overview

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company manufactures and distributes therapeutic products based on its hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, ORTHOVISC-T, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; and Tactoset, a synthetic, biocompatible hyaluronic acid-based bone graft substitute.The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; HYALOGRAN, HYAFF fibers used for orthopedic and trauma reconstructive surgical procedures; HYALOGLIDE used for the treatment of tendon, peripheral nerve, and articular surgeries; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

• What percentage of Anika Therapeutics is owned by insiders or institutions?

  Currently 4.043% of Anika Therapeutics shares are held by insiders and 99.609% by institutions.

• How many people work for Anika Therapeutics?

  Latest data suggests 154 work at Anika Therapeutics.

• When does the fiscal year end for Anika Therapeutics?

  Anika Therapeutics's fiscal year ends in December.

• Where is Anika Therapeutics based?

  Anika Therapeutics's address is: 32 Wiggins Avenue, Bedford, MA, United States, 01730

• What is Anika Therapeutics's ISIN number?

  Anika Therapeutics's international securities identification number is: US0352551081

• What is Anika Therapeutics's CUSIP number?

  Anika Therapeutics's Committee on Uniform Securities Identification Procedures number is: 035255108